1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Journal Article

    Lee, N. Y.; Ferris, R. L.; Psyrri, A.; Haddad, R. I.; Tahara, M.; Bourhis, J.; Harrington, K.; Chang, P. M. H.; Lin, J. C.; Razaq, M. A.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma: New targets and novel therapies
    Review

    Cheson, B. D.; Nowakowski, G.; Salles, G.
    Blood Cancer Journal (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma
    Journal Article

    Choueiri, T. K.; Powles, T.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Zurawski, B.; Oyervides Juárez, V. M.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; more...
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): A phase 1/2 study
    Journal Article

    Mato, A. R.; Shah, N. N.; Jurczak, W.; Cheah, C. Y.; Pagel, J. M.; Woyach, J. A.; Fakhri, B.; Eyre, T. A.; Lamanna, N.; Patel, M. R.; more...
    Lancet (2021)

    Fulltext@MSK | Save
  • Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
    Journal Article

    Laccetti, A. L.; Garmezy, B.; Xiao, L.; Economides, M.; Venkatesan, A.; Gao, J.; Jonasch, E.; Corn, P.; Zurita-Saavedra, A.; Brown, L. C.; more...
    Cancer Medicine (2021)

    Fulltext@MSK | Save
  • Symptom burden and willingness to participate: Implications for herbal clinical trials in lung cancer
    Journal Article

    Liu, J.; Hou, W.; Gönen, M.; Seluzicki, C.; Li, S. Q.; Mao, J. J.
    Annals of Palliative Medicine (2021)

    Fulltext@MSK | Save
  • Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
    Research Letter

    Lee, H. C.; Raje, N. S.; Landgren, O.; Upreti, V. V.; Wang, J.; Avilion, A. A.; Hu, X.; Rasmussen, E.; Ngarmchamnanrith, G.; Fujii, H.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: Results from a multicenter, randomized, phase 2/3 study
    Journal Article

    Montesinos, P.; Roboz, G. J.; Bulabois, C. E.; Subklewe, M.; Platzbecker, U.; Ofran, Y.; Papayannidis, C.; Wierzbowska, A.; Shin, H. J.; Doronin, V.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: An open-label, multicentre, phase 1b study
    Journal Article

    O'Hara, M. H.; O'Reilly, E. M.; Varadhachary, G.; Wolff, R. A.; Wainberg, Z. A.; Ko, A. H.; Fisher, G.; Rahma, O.; Lyman, J. P.; Cabanski, C. R.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
    Journal Article

    Alsina, M.; Landgren, O.; Raje, N.; Niesvizky, R.; Bensinger, W. I.; Berdeja, J. G.; Kovacsovics, T.; Vesole, D. H.; Fang, B.; Kimball, A. S.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save